The Institute for Clinical and Economic Review (ICER) has issued a draft report concluding four drugs have demonstrated effectiveness and value in reducing hospitalizations of COVID-19 patients. The independent nonprofit group evaluates prescription drugs and medical treatments’ cost effectiveness and relative improvement to quality of life. The organization is highly respected by medical professionals, insurers, pharmacy buyers and government policy makers in helping to determine which drugs are cost-effective and are worth the value.
The drugs are sotrovimab, a monoclonal antibody manufactured by Glaxo SmithKline and marketed as Xevudy; the antiviral molnupiravir, manufactured by Merck; antiviral ritonavir, a Pfizer product used to treat HIV infection; and fluvoxamine, a generic selective serotonin reuptake inhibitor used primarily to treat obsessive compulsive.
The Institute for Clinical and Economic Review (ICER) has issued a draft
report concluding four drugs have demonstrated effectiveness and value in reducing hospitalizations of COVID-19 patients.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
